AG vs EQX

The company exhibits weak financial health with a Piotroski F-Score of 4/9, indicating marginal stability, and lacks an Altman Z-Score, raising concerns about financial distress risk. Despite strong recent price performance and robust revenue growth (95.10% YoY), the stock appears significantly overvalued with a P/E of 169.60 versus sector average of 26.34 and a Graham Number of just $4.23, far below the current price of $25.44. Earnings quality is poor, with a track record of missing estimates in 3 of the last 4 quarters and an average surprise of -24.17%. While balance sheet metrics like low debt/equity (0.08) and strong liquidity (current ratio 3.38) are positives, weak ROE (4.21%) and inconsistent profitability undermine long-term value creation.

Equinox Gold presents a stark contrast between valuation and fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the stock is attractively valued with a Forward P/E of 7.91 and a strong analyst target of $23.00, the deterministic health metrics indicate significant operational instability. Recent price performance has been exceptional over the last year, but a 0/100 technical trend and a massive -83.33% Q/Q revenue decline suggest a looming correction or operational pivot. The investment profile is currently speculative, relying on gold price tailwinds rather than internal financial strength.